» Articles » PMID: 30355114

Clinical Outcomes and Neuroimaging Profiles in Nondisabled Patients With Anticoagulant-Related Intracerebral Hemorrhage

Abstract

Background and Purpose- The aim of this study was to prospectively validate our prior findings of smaller hematoma volume and lesser neurological deficit in nonvitamin K oral anticoagulant (NOAC) compared with Vitamin K antagonist (VKA)-related intracerebral hemorrhage (ICH). Methods- Prospective 12-month observational study in 15 tertiary stroke centers in the United States, Europe, and Asia. Consecutive patients with premorbid modified Rankin Scale score of <2 with acute nontraumatic anticoagulant-related ICH divided into 2 groups according to the type of anticoagulant: NOAC versus VKA. We recorded baseline ICH volume, significant hematoma expansion (absolute [12.5 mL] or relative [>33%] increase), neurological severity measured by National Institutes of Health Stroke Scale score, 90-day mortality, and functional status (modified Rankin Scale score). Results- Our cohort comprised 196 patients, 62 NOAC related (mean age, 75.0±11.4 years; 54.8% men) and 134 VKA related (mean age, 72.3±10.5; 73.1% men). There were no differences in vascular comorbidities, antiplatelet, and statin use; NOAC-related ICH patients had lower median baseline hematoma volume (13.8 [2.5-37.6] versus 19.5 [6.6-52.0] mL; P=0.026) and were less likely to have severe neurological deficits (National Institutes of Health Stroke Scale score of >10 points) on admission (37% versus 55.3%, P=0.025). VKA-ICH were more likely to have significant hematoma expansion (37.4% versus 17%, P=0.008). NOAC pretreatment was independently associated with smaller baseline hematoma volume (standardized linear regression coefficient:-0.415 [95% CI, -0.780 to -0.051]) resulting in lower likelihood of severe neurological deficit (odds ratio, 0.44; 95% CI, 0.22-0.85) in multivariable-adjusted models. Conclusions- Patients with NOAC-related ICH have smaller baseline hematoma volumes and lower odds of severe neurological deficit compared with VKA-related ICH. These findings are important for practicing clinicians making anticoagulation choices.

Citing Articles

Trends in prior antithrombotic medication and risk of in-hospital mortality after spontaneous intracerebral hemorrhage: the J-ICH registry.

Ueno H, Tokugawa J, Saito R, Yamashiro K, Tsutsumi S, Yamamoto M Sci Rep. 2024; 14(1):12009.

PMID: 38796624 PMC: 11127931. DOI: 10.1038/s41598-024-62717-5.


Intracerebral haemorrhage in patients taking different types of oral anticoagulants: a pooled individual patient data analysis from two national stroke registries.

Siepen B, Forfang E, Branca M, Drop B, Mueller M, Goeldlin M Stroke Vasc Neurol. 2024; 9(6):640-651.

PMID: 38336370 PMC: 11791643. DOI: 10.1136/svn-2023-002813.


A Combination of Ex Vivo and In Vivo Strategies for Evaluating How Much New Oral Anticoagulants Exacerbate Experimental Intracerebral Bleeding.

Ferreira J, Sucupira I, Carvalho G, Paiva F, Pimentel-Coelho P, Rosado-de-Castro P TH Open. 2023; 7(3):e195-e205.

PMID: 37435564 PMC: 10332909. DOI: 10.1055/s-0043-1770782.


Is a high chest CT severity score a risk factor for an increased incidence of long-term neuroimaging findings after COVID-19?.

Kaya A, Akman B J Stroke Cerebrovasc Dis. 2022; 32(2):106920.

PMID: 36516593 PMC: 9708621. DOI: 10.1016/j.jstrokecerebrovasdis.2022.106920.


Decision-Making Process for the Management of Acute Stroke in Patients on Oral Anticoagulant: From Guidelines to Clinical Routine.

Sibon I, Mazighi M, Smadja D Front Neurol. 2022; 12:794001.

PMID: 35069423 PMC: 8766998. DOI: 10.3389/fneur.2021.794001.


References
1.
Hankey G, Stevens S, Piccini J, Lokhnygina Y, Mahaffey K, Halperin J . Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial.... Stroke. 2014; 45(5):1304-12. DOI: 10.1161/STROKEAHA.113.004506. View

2.
Anderson C, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C . Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013; 368(25):2355-65. DOI: 10.1056/NEJMoa1214609. View

3.
Brouwers H, Greenberg S . Hematoma expansion following acute intracerebral hemorrhage. Cerebrovasc Dis. 2013; 35(3):195-201. PMC: 3743539. DOI: 10.1159/000346599. View

4.
Hemphill 3rd J, Greenberg S, Anderson C, Becker K, Bendok B, Cushman M . Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015; 46(7):2032-60. DOI: 10.1161/STR.0000000000000069. View

5.
Krishnan K, Mukhtar S, Lingard J, Houlton A, Walker E, Jones T . Performance characteristics of methods for quantifying spontaneous intracerebral haemorrhage: data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. J Neurol Neurosurg Psychiatry. 2015; 86(11):1258-66. PMC: 4680163. DOI: 10.1136/jnnp-2014-309845. View